
Yihua Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8319784/publications.pdf Version: 2024-02-01



Υιμιία Ζμανις

#	Article	IF	CITATIONS
1	Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. Journal of Medicinal Chemistry, 2017, 60, 7617-7635.	2.9	260
2	Nanoscale Coordination Polymers for Synergistic NO and Chemodynamic Therapy of Liver Cancer. Nano Letters, 2019, 19, 2731-2738.	4.5	158
3	Dual Intratumoral Redox/Enzymeâ€Responsive NOâ€Releasing Nanomedicine for the Specific, Highâ€Efficacy, and Lowâ€Toxic Cancer Therapy. Advanced Materials, 2018, 30, e1704490.	11.1	155
4	The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice. International Immunopharmacology, 2015, 25, 55-64.	1.7	143
5	Tacrine–Ferulic Acid–Nitric Oxide (NO) Donor Trihybrids as Potent, Multifunctional Acetyl- and Butyrylcholinesterase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 4309-4321.	2.9	122
6	Design, Synthesis, and Antihepatocellular Carcinoma Activity of Nitric Oxide Releasing Derivatives of Oleanolic Acid. Journal of Medicinal Chemistry, 2008, 51, 4834-4838.	2.9	97
7	New techniques and strategies in drug discovery. Chinese Chemical Letters, 2020, 31, 1695-1708.	4.8	82
8	Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2013, 56, 4738-4748.	2.9	67
9	Synthesis of CDDO–Amino Acid–Nitric Oxide Donor Trihybrids as Potential Antitumor Agents against Both Drug-Sensitive and Drug-Resistant Colon Cancer. Journal of Medicinal Chemistry, 2015, 58, 2452-2464.	2.9	65
10	Novel Nitric Oxide-Releasing Derivatives of Farnesylthiosalicylic Acid: Synthesis and Evaluation of Antihepatocellular Carcinoma Activity. Journal of Medicinal Chemistry, 2011, 54, 3251-3259.	2.9	61
11	Hybrid Molecule from <i>O</i> ² -(2,4-Dinitrophenyl)diazeniumdiolate and Oleanolic Acid: A Glutathione <i>S</i> -Transferase π-Activated Nitric Oxide Prodrug with Selective Anti-Human Hepatocellular Carcinoma Activity and Improved Stability. Journal of Medicinal Chemistry, 2013, 56, 4641-4655.	2.9	55
12	Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid. Organic and Biomolecular Chemistry, 2010, 8, 632-639.	1.5	49
13	Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6416-6420.	1.0	45
14	Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo. Journal of Medicinal Chemistry, 2018, 61, 1821-1832.	2.9	45
15	Discovery of a Potential Anti-Ischemic Stroke Agent: 3-Pentylbenzo[<i>c</i>]thiophen-1(3 <i>H</i>)-one. Journal of Medicinal Chemistry, 2012, 55, 7173-7181.	2.9	44
16	(S)-ZJM-289, a nitric oxide-releasing derivative of 3-n-butylphthalide, protects against ischemic neuronal injury by attenuating mitochondrial dysfunction and associated cell death. Neurochemistry International, 2012, 60, 134-144.	1.9	40
17	Anti-CD24 Antibody–Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. Cancer Research, 2019, 79, 3395-3405.	0.4	39
18	Novel Hybrids of Optically Active Ring-Opened 3-n-Butylphthalide Derivative and Isosorbide as Potential Anti-Ischemic Stroke Agents. Journal of Medicinal Chemistry, 2013, 56, 3078-3089.	2.9	38

Yihua Zhang

#	Article	IF	CITATIONS
19	Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. Bioorganic and Medicinal Chemistry, 2010, 18, 3448-3456.	1.4	37
20	Design, synthesis and evaluation of nitric oxide releasing derivatives of 3-n-butylphthalide as antiplatelet and antithrombotic agents. Organic and Biomolecular Chemistry, 2011, 9, 5670.	1.5	37
21	Synthesis and Biological Evaluation of Novel Furozan-Based Nitric Oxide-Releasing Derivatives of Oridonin as Potential Anti-Tumor Agents. Molecules, 2012, 17, 7556-7568.	1.7	33
22	Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3535-3540.	1.0	33
23	Potent Inhibition of Nitric Oxide-Releasing Bifendate Derivatives against Drug-Resistant K562/A02 Cells in Vitro and in Vivo. Journal of Medicinal Chemistry, 2017, 60, 928-940.	2.9	32
24	Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors. European Journal of Medicinal Chemistry, 2012, 51, 137-144.	2.6	31
25	Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2795-2800.	1.0	31
26	Anticancer efficacy of a nitric oxideâ€modified derivative of bifendate against multidrugâ€resistant cancer cells. Journal of Cellular and Molecular Medicine, 2016, 20, 1095-1105.	1.6	30
27	Identification of New Nitric Oxide-Donating Peptides with Dual Biofilm Eradication and Antibacterial Activities for Intervention of Device-Related Infections. Journal of Medicinal Chemistry, 2020, 63, 9127-9135.	2.9	30
28	Discovery of a ring-opened derivative of 3-n-butylphthalide bearing NO/H2S-donating moieties as a potential anti-ischemic stroke agent. European Journal of Medicinal Chemistry, 2016, 115, 369-380.	2.6	29
29	Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy. Journal of Medicinal Chemistry, 2017, 60, 8847-8857.	2.9	29
30	Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents. Journal of Medicinal Chemistry, 2015, 58, 4506-4520.	2.9	27
31	Design, synthesis and biological evaluation of hydrogen sulfide releasing derivatives of 3-n-butylphthalide as potential antiplatelet and antithrombotic agents. Organic and Biomolecular Chemistry, 2014, 12, 5995-6004.	1.5	26
32	Synthesis and evaluation of N -heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents. European Journal of Medicinal Chemistry, 2017, 138, 313-319.	2.6	26
33	Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents. Organic and Biomolecular Chemistry, 2012, 10, 3882.	1.5	22
34	General Strategy for Integrated Bioorthogonal Prodrugs: Pt(II)-Triggered Depropargylation Enables Controllable Drug Activation <i>In Vivo</i> . Journal of Medicinal Chemistry, 2020, 63, 13899-13912.	2.9	22
35	Synthesis and Evaluation of <i>O</i> ² -Derived Diazeniumdiolates Activatable via Bioorthogonal Chemistry Reactions in Living Cells. Organic Letters, 2018, 20, 2164-2167.	2.4	21
36	From Seeds of <i>Apium graveolens</i> Linn. to a Cerebral Ischemia Medicine: The Long Journey of 3- <i>n</i> -Butylphthalide. Journal of Medicinal Chemistry, 2020, 63, 12485-12510.	2.9	21

Yihua Zhang

#	Article	IF	CITATIONS
37	Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana- 9-dien-28-oic acid and O 2 -(2,4-dinitrophenyl) diazeniumdiolate for intervention of drug-resistant lung cancer. European Journal of Medicinal Chemistry, 2018, 149, 269-280.	2.6	20
38	ldentification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats. Journal of Medicinal Chemistry, 2018, 61, 1474-1482.	2.9	20
39	<i>O</i> ² -3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation <i>via</i> nitric oxide-based epigenetic regulation. Chemical Science, 2018, 9, 6893-6898.	3.7	20
40	<i>O</i> ² -Sulfonylethyl Protected Isopropylamine Diazen-1-ium-1,2-diolates as Nitroxyl (HNO) Donors: Synthesis, β-Elimination Fragmentation, HNO Release, Positive Inotropic Properties, and Blood Pressure Lowering Studies. Journal of Medicinal Chemistry, 2012, 55, 10262-10271.	2.9	19
41	Synthesis and biological evaluation of nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide as potential antiplatelet agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1985-1988.	1.0	18
42	Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 801-805.	1.0	17
43	Glutathione <i>S</i> -Transferase π-Activatable <i>O</i> ² -(Sulfonylethyl Derived) Diazeniumdiolates Potently Suppress Melanoma in Vitro and in Vivo. Journal of Medicinal Chemistry, 2018, 61, 1833-1844.	2.9	17
44	Protein <i>S</i> -Nitrosation: Biochemistry, Identification, Molecular Mechanisms, and Therapeutic Applications. Journal of Medicinal Chemistry, 2022, 65, 5902-5925.	2.9	17
45	(S)-ZJM-289 Preconditioning Induces a Late Phase Protection Against Nervous Injury Induced by Transient Cerebral Ischemia and Oxygen-Glucose Deprivation. Neurotoxicity Research, 2014, 26, 16-31.	1.3	16
46	Synthesis and evaluation of novel O ² -derived diazeniumdiolates as photochemical and real-time monitoring nitric oxide delivery agents. Organic Chemistry Frontiers, 2017, 4, 2445-2449.	2.3	16
47	Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors. European Journal of Medicinal Chemistry, 2019, 184, 111750.	2.6	15
48	Studies on the enantiomers of ZJM-289: synthesis and biological evaluation of antiplatelet, antithrombotic and neuroprotective activities. Organic and Biomolecular Chemistry, 2012, 10, 9030.	1.5	14
49	Design, Synthesis, and Evaluation of Diazeniumdiolate-Based DNA Cross-Linking Agents Activatable by Glutathione S-Transferase. Organic Letters, 2016, 18, 5196-5199.	2.4	14
50	Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches. European Journal of Medicinal Chemistry, 2017, 138, 199-211.	2.6	14
51	<i>>O</i> ² -(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTÏ€ with both anti-proliferative and anti-metastatic activities against melanoma. Chemical Communications, 2017, 53, 5059-5062.	2.2	13
52	Systematic study of imidazoles inhibiting IDO1 via the integration of molecular mechanics and quantum mechanics calculations. European Journal of Medicinal Chemistry, 2017, 131, 152-170.	2.6	13
53	8e Protects against Acute Cerebral Ischemia by Inhibition of PI3KÎ ³ -Mediated Superoxide Generation in Microglia. Molecules, 2018, 23, 2828.	1.7	11
54	Design and synthesis of the ring-opened derivative of 3-n-butylphthalide-ferulic acid-glucose trihybrids as potential anti-ischemic agents. Chinese Chemical Letters, 2020, 31, 1881-1886.	4.8	10

YIHUA ZHANG

#	Article	IF	CITATIONS
55	Identification of nitric oxide-releasing derivatives of oleanolic acid as potential anti-colon cancer agents. RSC Advances, 2015, 5, 19445-19454.	1.7	9
56	Design, Synthesis, and Biological Evaluation of Organic Nitrite (NO ₂ [–]) Donors as Potential Anticerebral Ischemia Agents. Journal of Medicinal Chemistry, 2021, 64, 10919-10933.	2.9	7
57	5d, a novel analogue of 3-n-butylphthalide, protects brains against nervous injury induced by ischemia/reperfusion through Akt/Nrf2/NOX4 signaling pathway. RSC Advances, 2015, 5, 69583-69592.	1.7	6
58	Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance. European Journal of Medicinal Chemistry, 2019, 162, 650-665.	2.6	6
59	Tetrazine-mediated bioorthogonal removal of 3-isocyanopropyl groups enables the controlled release of nitric oxide <i>in vivo</i> . Biomaterials Science, 2021, 9, 1816-1825.	2.6	6
60	Discovery of phosphorodiamidate mustard-based O2-phosphorylated diazeniumdiolates with potent anticancer activity. RSC Advances, 2017, 7, 18893-18899.	1.7	5
61	Enantiomers of 3-pentylbenzo[c]thiophen-1(3H)-one: preparation and evaluation of anti-ischemic stroke activities. RSC Advances, 2016, 6, 36888-36897.	1.7	4
62	Synthesis and biological evaluation of hybrids from optically active ring-opened 3-N-butylphthalide derivatives and 4-fluro-edaravone as potential anti-acute ischemic stroke agents. Bioorganic and Medicinal Chemistry, 2022, 69, 116891.	1.4	3